MarketMaestro

$TSLA
It was able to stay strong during this process. In fact, if it catches a good market, the setup could turn bullish. It’s at a decision point. ...We’ll understand better what it will do this week

$SHOP
It reacted from the $105 EMA support and the first FVG (blue area) zone up to the averages. This week is critical; .., ... The daily setup looks good. There is a double bottom, and there is a good breakout on RSI. .. This depth is enough for a handle and it is in a good position for the next quarter

Futures are slightly red

$MSFT
It is being hurt by both SaaS and now the cybersecurity side. The decline had already started because of CapEx. 2026 will be challenging for $MSFT, $META, and $AMZN. Wall Street is wondering whether they will be able to succeed or not. There is still no stabilization or consolidation look. ..

$KOS
There is a massive double bottom, and it is rising very strongly from the bottom. ..it may benefit positively from U.S.-Iran tensions. ..

$PATH
It made an inverse breakout back below the red diagonal resistance it had previously broken. If it makes a monthly close below the green line, things could completely break down..

$HGRAF
HydroGraph is a company that produces industrial-scale, high purity (99.8%) fractal and reactive graphene, as well as hydrogen, using patented explosion/detonation technology. Although graphene has been described as a miracle material for years, its commercialization has been slow because production is expensive and difficult; HydroGraph claims that with its modular system called Hyperion, it has made this process cheaper, scalable, and environmentally friendly. It trades on the OTC market.
It contains very large future pricing expectations, but it can be just as brutal. HydroGraph’s pr

$IBRX
ImmunityBio is a commercial stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. The company’s flagship product is an immunotherapy called ANKTIVA, used especially in bladder cancer and, with recent approvals, in lung cancer treatments.
The biotechnology sector is inherently high risk, and pricing is generally tied to the approval/sales success of a single drug. ImmunityBio’s performance in recent months depends on whether Anktiva can move beyond being just an expectation and become a global product that directly writes cash into the bal

$SATL
They do a similar business to $PL, but it appeals to people whose risk profile is suited to aggressive growth and it’s a volatile stock. The move it’s making right now looks like a reaction bounce from the average after an excessive drop. .. It retested the FVG, ..

Why Is Advice from Someone Who Doesn’t Know Technical Analysis a Disaster? 👇
Trying to give stock recommendations or manage a portfolio without knowing technical analysis is no different than trying to cross an ocean with an airplane whose instrument panel is broken and has no navigation. No matter how strong the plane’s engine is, if you can’t see the direction of the wind and the storms, crashing is only a matter of time.
Fundamental Analysis Tells You "What" to Buy, Technical Analysis Tells You "When" to Buy
You may find a company with great financial statements that is at the center of a

$EOSE
After starting the rally, despite everything that happened, the support band always worked as the bottom 🤞

$NDX
I turned Nasdaq into a chart adjusted for real inflation.
Why? Nominal charts only show that the number on the screen is going up. While the $SPX or Nasdaq may be making new highs in nominal terms, the currency may also be being devalued in the background. An inflation adjusted chart shows us real growth.
In short, I wanted a smoother and better view. The index is at the important fibo1.618 resistance zone, and for that reason it is struggling. Also, there is a very obvious cup+handle setup on the index, and it tells us the future will be bullish 💯
On the other hand, if the ... support z

$SMR
Now it’s down to miracles. $.., the last price, is the final defensive line. If it can’t see a recovery like the one in the boxed area, the chart will break. .. It’s in an extremely risky situation

$KTOS
It’s benefiting positively from the U.S.–Iran tension. But the risk hasn’t passed. After hitting the correction band, could you look at the RSI? An H+S setup formed. .. If you look at the weekly view, there’s a very similar setup to $ONDS. .

$RBRK
It looks bad. There’s no stabilization or consolidation. .. It’s in an extremely risky position. ..

$QS
Pre revenue companies like QS regularly need external financing to keep operations going. When risk appetite is strong, they can usually raise this funding relatively cheaply through equity sales (secondary offerings/ATM programs) or more flexible, equity like instruments. Right now, risk appetite is weak. But if liquidity tightens and capital markets close to these kinds of companies, the option set deteriorates quickly: as access to capital worsens, the company either turns to more expensive and more tightly structured financings (like converts/PIPE/structured equity), or it increases di

$SOFI
It pulled back to $18.78-EMA21. Decision time!

$OKLO
I’m basing it on the previous cycle, and I’m hopeful for the no4 bottom! 🤞

$CPNG
If I base it on the behavior of the old FVG zone (the blue area), this area may have bottomed 🤞